247 related articles for article (PubMed ID: 27793057)
1. Hypermethylation of the HIC1 promoter and aberrant expression of HIC1/SIRT1 contribute to the development of thyroid papillary carcinoma.
Wu W; Zhang L; Lin J; Huang H; Shi B; Lin X; Huang Z; Wang C; Qiu J; Wei X
Oncotarget; 2016 Dec; 7(51):84416-84427. PubMed ID: 27793057
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer.
Zhao G; Qin Q; Zhang J; Liu Y; Deng S; Liu L; Wang B; Tian K; Wang C
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S301-11. PubMed ID: 22552606
[TBL] [Abstract][Full Text] [Related]
3. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
4. Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients.
Tseng RC; Lee CC; Hsu HS; Tzao C; Wang YC
Neoplasia; 2009 Aug; 11(8):763-70. PubMed ID: 19649206
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses.
Chen WY; Wang DH; Yen RC; Luo J; Gu W; Baylin SB
Cell; 2005 Nov; 123(3):437-48. PubMed ID: 16269335
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylated in cancer 1 (HIC1) mediates high glucose induced ROS accumulation in renal tubular epithelial cells by epigenetically repressing SIRT1 transcription.
Zeng S; Wu X; Chen X; Xu H; Zhang T; Xu Y
Biochim Biophys Acta Gene Regul Mech; 2018 Oct; 1861(10):917-927. PubMed ID: 30496037
[TBL] [Abstract][Full Text] [Related]
7. Molecular dissection of the interaction between HIC1 and SIRT1.
Dehennaut V; Loison I; Pinte S; Leprince D
Biochem Biophys Res Commun; 2012 May; 421(2):384-8. PubMed ID: 22510409
[TBL] [Abstract][Full Text] [Related]
8. Demethylation treatment restores hic1 expression and impairs aggressiveness of head and neck squamous cell carcinoma.
Brieger J; Pongsapich W; Mann SA; Hedrich J; Fruth K; Pogozelski B; Mann WJ
Oral Oncol; 2010 Sep; 46(9):678-83. PubMed ID: 20729134
[TBL] [Abstract][Full Text] [Related]
9. Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.
Sassa M; Hayashi Y; Watanabe R; Kikumori T; Imai T; Kurebayashi J; Kiuchi T; Murata Y
Thyroid; 2011 May; 21(5):511-7. PubMed ID: 21449767
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma.
Huang Y; de la Chapelle A; Pellegata NS
Int J Cancer; 2003 May; 104(6):735-44. PubMed ID: 12640681
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma.
Li JY; Han C; Zheng LL; Guo MZ
Chin Med J (Engl); 2012 Oct; 125(19):3526-31. PubMed ID: 23044318
[TBL] [Abstract][Full Text] [Related]
12. HIC1 modulates prostate cancer progression by epigenetic modification.
Zheng J; Wang J; Sun X; Hao M; Ding T; Xiong D; Wang X; Zhu Y; Xiao G; Cheng G; Zhao M; Zhang J; Wang J
Clin Cancer Res; 2013 Mar; 19(6):1400-10. PubMed ID: 23340301
[TBL] [Abstract][Full Text] [Related]
13. SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis.
Li H; Tian Z; Qu Y; Yang Q; Guan H; Shi B; Ji M; Hou P
Oncogene; 2019 Jan; 38(3):345-359. PubMed ID: 30093629
[TBL] [Abstract][Full Text] [Related]
14. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Rasti M; Tavasoli P; Monabati A; Entezam M
Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345
[TBL] [Abstract][Full Text] [Related]
15. HIC1 (hypermethylated in cancer 1) SUMOylation is dispensable for DNA repair but is essential for the apoptotic DNA damage response (DDR) to irreparable DNA double-strand breaks (DSBs).
Paget S; Dubuissez M; Dehennaut V; Nassour J; Harmon BT; Spruyt N; Loison I; Abbadie C; Rood BR; Leprince D
Oncotarget; 2017 Jan; 8(2):2916-2935. PubMed ID: 27935866
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation signatures identify biologically distinct thyroid cancer subtypes.
Rodríguez-Rodero S; Fernández AF; Fernández-Morera JL; Castro-Santos P; Bayon GF; Ferrero C; Urdinguio RG; Gonzalez-Marquez R; Suarez C; Fernández-Vega I; Fresno Forcelledo MF; Martínez-Camblor P; Mancikova V; Castelblanco E; Perez M; Marrón PI; Mendiola M; Hardisson D; Santisteban P; Riesco-Eizaguirre G; Matías-Guiu X; Carnero A; Robledo M; Delgado-Álvarez E; Menéndez-Torre E; Fraga MF
J Clin Endocrinol Metab; 2013 Jul; 98(7):2811-21. PubMed ID: 23666970
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylated in cancer 1(HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway.
Wang X; Wang Y; Xiao G; Wang J; Zu L; Hao M; Sun X; Fu Y; Hu G; Wang J
Oncotarget; 2016 May; 7(21):30350-64. PubMed ID: 27107418
[TBL] [Abstract][Full Text] [Related]
18. ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a.
Qiang W; Zhao Y; Yang Q; Liu W; Guan H; Lv S; Ji M; Shi B; Hou P
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1163-72. PubMed ID: 24684457
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive silencing of target-sharing microRNAs is a mechanism for SIRT1 overexpression in cancer.
Kiga K; Fukuda-Yuzawa Y; Tanabe M; Tsuji S; Sasakawa C; Fukao T
RNA Biol; 2014; 11(11):1347-54. PubMed ID: 25483038
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas.
Kondo T; Nakazawa T; Ma D; Niu D; Mochizuki K; Kawasaki T; Nakamura N; Yamane T; Kobayashi M; Katoh R
Lab Invest; 2009 Jul; 89(7):791-9. PubMed ID: 19506552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
